In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.
Commentary|Podcasts|February 6, 2026
Pharma Pulse: PBM Reform Hits the Courtroom and Telehealth’s Legislative Victory
Author(s)Nicholas Saraceno, Senior Editor
In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.
Advertisement
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.
- The FTC has finalized a
landmark settlement with Express Scripts, targeting the "rebate trap." The agreement aims to dismantle anticompetitive practices that the FTC alleges artificially inflated the price of life-saving medications like insulin. With $7 billion in projected relief for patients over the next decade, the deal mandates a total overhaul of how rebates are handled, forcing PBMs to prioritize lower list prices over hidden kickbacks. - Meanwhile, digital health is here to stay. In the latest federal budget package, lawmakers have officially extended
critical telehealth flexibilities for Medicare beneficiaries. This "win-win" provision removes the threat of a telehealth cliff, ensuring that providers can continue to offer remote care without the fear of sudden reimbursement cuts. It’s a major victory for rural access and chronic disease management.
That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit
Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on
Advertisement
Related to this article
PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
LogiPharma USA 2026: Data Readiness Must Come Before AI
2
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
3
Why PhRMA Sued to Block Medicare's GLOBE Pricing Model
4
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
5